C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 814—Premarket Approval of Medical DevicesSubpart E—Postapproval Requirements

21 C.F.R. § 814.84 (2026)

Reports

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1995–2026 49citing cases
At a glance

Courts have cited this section in 49 opinions since 1995, 7 of them in the last five years.

(a) The holder of an approved PMA shall comply with the requirements of part 803 and with any other requirements applicable to the device by other regulations in this subchapter or by order approving the device.

(b) Unless FDA specifies otherwise, any periodic report shall:

(1) Identify changes described in § 814.39(a) and changes required to be reported to FDA under § 814.39(b).

(2) Contain a summary and bibliography of the following information not previously submitted as part of the PMA:

(i) Unpublished reports of data from any clinical investigations or nonclinical laboratory studies involving the device or related devices and known to or that reasonably should be known to the applicant.

(ii) Reports in the scientific literature concerning the device and known to or that reasonably should be known to the applicant. If, after reviewing the summary and bibliography, FDA concludes that the agency needs a copy of the unpublished or published reports, FDA will notify the applicant that copies of such reports shall be submitted.

(3) Identify changes made pursuant to an exception or alternative granted under § 801.128 or § 809.11 of this chapter.

(4) Identify each device identifier currently in use for the device, and each device identifier for the device that has been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013.

[51 FR 26364, July 22, 1986, as amended at 51 FR 43344, Dec. 2, 1986; 67 FR 9587, Mar. 4, 2002; 72 FR 73602, Dec. 28, 2007; 78 FR 58822, Sept. 24, 2013]
The 20 cases that cite 21 C.F.R. § 814.84 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRiegel v. Medtronic, Inc., 451 F.3d 104 (2d Cir. 2006).
cites § 814.84 7×cited by 104 cases
Where it cites § 814.84
“Additionally, the standard FDA “Conditions of Approval” accompanying a PMA order state that continued approval of the PMA “is contingent on the submission of postapproval reports required under 21 CFR 814.84 at intervals of 1 year from the date of approval of the original PMA.”
The case’s holding
State common law tort claims alleging liability based on a medical device's adherence to FDA premarket approval standards are preempted by the Medical Device Amendments.
Later courts cite it for
“an expert opinion requires some explanation as to how the expert came to his conclusion and what methodologies or evidence substantiate that conclusion.” · 26 citing courts
2
GREENRiegel v. Medtronic, Inc., 552 U.S. 312 (2008).
cites § 814.84 2×cited by 725 cases
Where it cites § 814.84
“These include the obligation to inform the FDA of new clinical investigations or scientific studies concerning the device which the applicant knows of or reasonably should know of, 21 CFR § 814.84 (b)(2), and to report incidents in which the device may have caused or contributed…”
The case’s holding
The Medical Device Amendments preclude state law claims that impose requirements different from, or in addition to, federal requirements regarding a device that received premarket approval.
Later courts cite it for
“360k does not prevent a state from providing a damages remedy for claims premised on a violation of fda regulations; the state duties in such a case 'parallel,' rather than add to, federal requirements.” · 102 citing courts
3
GREENBlunt v. Medtronic, Inc., 2009 WI 16, 760 N.W.2d 396.
cites § 814.84 4×cited by 17 cases
Where it cites § 814.84
“These include the obligation to inform the FDA of new clinical investigations or scientific studies concerning the device which the applicant knows of or reasonably should know of, 21 C.F.R. § 814.84 (b)(2), and to report incidents in which the device may have caused or…”
The case’s holding
State tort claims challenging the safety of a Class III medical device are expressly preempted where the device received device-specific FDA premarket approval, absent withdrawal of that approval.
Later courts cite it for
“we review a summary judgment decision independently, employing the same methodology as the circuit court,” · 2 citing courts
4
GREENElizabeth & Clifford Kemp v. Medtronic, Inc., 231 F.3d 216 (6th Cir. 2000).
cites § 814.84 2×cited by 107 cases
Where it cites § 814.84
“Building on Count I, Count II alleges that Medtronic was required by the conditions of approval set forth in 21 C.F.R. § 814.84 to seek FDA approval for any change affecting the “safety and effectiveness of the device.”
The case’s holding
FDA approval of a premarket approval supplement and its accompanying conditions constitute specific federal requirements that preempt state law claims under the Medical Device Amendments.
Later courts cite it for
“to the extent that plaintiffs' claim is premised on the adequacy of the warnings reviewed and approved by the fda . . . the claim is . . . preempted.” · 5 citing courts
5
GREENSherry Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012).
cites § 814.84 2×cited by 29 cases
Where it cites § 814.84
“21 C.F.R. § 814.84 (b). "The FDA has the power to withdraw premarket approval based on newly reported data or existing information and must withdraw approval if it determines that a device is unsafe or ineffective under the conditions in its labeling.”
The case’s holding
Common law tort claims are preempted by the Medical Device Amendments if they impose requirements different from or in addition to the terms of a Class III device's premarket approval.
Later courts cite it for
“a common law tort claim that presupposes a class iii device should have been designed in a manner other than that contemplated by its premarket approval is therefore expressly preempted by the mda as interpreted by riegel.” · 3 citing courts
6
GREENWaltenburg v. St. Jude Med., Inc., 33 F. Supp. 3d 818 (W.D. Ky. 2014).
cites § 814.84 2×cited by 23 cases
Where it cites § 814.84
“§ 360i; 21 C.F.R. § 814.84 . These requirements include the obligation to submit periodic reports to the FDA informing the agency of any “[u]n-published reports of data from any clinical investigations or nonclinical laboratory studies involving the device” as well as any…”
7
GREENWhite v. Stryker Corp., 818 F. Supp. 2d 1032 (W.D. Ky. 2011).
cites § 814.84 2×cited by 18 cases
Where it cites § 814.84
“The standard FDA “Conditions of Approval” accompanying a PMA approval order state that continued approval of the PMA “is contingent on the submission of postapproval reports required under 21 C.F.R. 814.84 at intervals of 1 year from the date of approval of the original PMA.”
Later courts cite it for
“a plausible cause of action requires, among other things, a showing that the alleged violation of state law parallels a violation of federal law.” · 2 citing courts
8
GREENRamirez v. Medtronic Inc., 961 F. Supp. 2d 977 (D. Ariz. 2013).
cites § 814.84 1×cited by 46 cases
Where it cites § 814.84
“For example, the manufacturer must update the FDA when it learns of investigations or scientific studies concerning its device, 21 C.F.R. § 814.84 (b)(2), or incidents where the device — used in any manner — “[m]ay have caused or contributed to a death or serious injury,” either…”
The case’s holding
Federal preemption does not bar state law claims arising from a medical device manufacturer's promotion of off-label uses that have not been reviewed by the FDA.
Later courts cite it for
“affirmation that forms the basis of an express warranty must be between the seller and the buyer.” · 2 citing courts
9
GREENClark v. Medtronic, Inc., 572 F. Supp. 2d 1090 (D. Minn. 2008).
cites § 814.84 2×cited by 12 cases
Where it cites § 814.84
“The manufacturer must also report the results of new scientific studies or investigations related to the safety or effectiveness of the device on an ongoing basis, 21 C.F.R. § 814.84 (b)(2), along with- any incidents where the device caused death or serious injury, or where it…”
Later courts cite it for
“as the supreme court aptly recognized in riegel, the premarket approval process is ultimately a cost- benefit analysis in which the potential health benefits are weighed against the potential risks.” · 2 citing courts
10
GREENConklin v. Medtronic Inc, 431 P.3d 571 (Ariz. 2018).
cites § 814.84 1×cited by 15 cases
Where it cites § 814.84
“(citing 21 C.F.R. § 814.84 (b)(2) ), "and to report incidents in which the device may have caused or contributed to death or serious injury[ ] or malfunctioned in a manner that would likely cause or contribute to death or serious injury if it recurred," id.”
Later courts cite it for
“watts adopted the restatement (third) of torts provision in 6(d) that 8 sets forth the doctrine for prescription drug and medical device manufacturers.” · 2 citing courts
11
GREENMcClelland v. Medtronic, Inc., 944 F. Supp. 2d 1193 (M.D. Fla. 2013).
cites § 814.84 2×cited by 11 cases
Where it cites § 814.84
“Moreover, after PMA, manufacturers are subject to reporting requirements.”
Later courts cite it for
“an attempt to recast a claim for violation of the fdca as a state-law negligence claim.” · 3 citing courts
12
GREENGelber v. Stryker Corp., 788 F. Supp. 2d 145 (S.D.N.Y. 2011).
cites § 814.84 1×cited by 40 cases
Where it cites § 814.84
“21 C.F.R. § 814.84 (b)(2). Manufacturers must also report incidents in which the device “[m]ay have caused or contributed to a death or serious injury” or “[h]as malfunctioned and this device or a similar device [marketed by the manufacturer] would be likely to cause or…”
The case’s holding
A state law manufacturing defect claim is not preempted if the complaint provides adequate notice by describing the conduct that violates federal current good manufacturing practice requirements.
Later courts cite it for
“a statute of limitations defense, based exclusively on dates contained within the complaint or appended materials, may be properly asserted by a defendant in a rule 12(b)(6) motion.” · 3 citing courts
13
GREENSteele v. Collagen Corp., 54 Cal. App. 4th 1474 (Ct. App. 1997).
cites § 814.84 2×cited by 24 cases
The case’s holding
State law claims regarding device safety and effectiveness are preempted when they impose requirements different from or in addition to federal requirements resulting from the PMA process.
Later courts cite it for
“while the design or labeling of a device may be changed to enhance the safety without prior approval from the fda, the manufacturer must submit to the fda a pma supplement and obtain acknowledgment from the fda of receipt of the supplement. ( 21 c.f.r. 814.39 (1996).) the device is still subject to withdrawal from the market if the fda determines any changes have rendered it unsafe or the labeling inadequate.” · 2 citing courts
14
GREENCaplinger v. Medtronic, Inc., 921 F. Supp. 2d 1206 (W.D. Okla. 2013).
cites § 814.84 1×cited by 37 cases
Where it cites § 814.84
“These include the obligation to inform the FDA of new clinical investigations or scientific studies concerning the device which the applicant knows of or reasonably should know of, 21 CFR § 814.84 (b)(2), and to report incidents in which the device may have caused or contributed…”
The case’s holding
State law claims based on off-label promotion are impliedly preempted because the concept of off-label use is defined by federal law rather than state substantive law.
Later courts cite it for
“even the concept of 'off-label use' is a creature of the fdca, is defined by the fdca, and is not a part of oklahoma substantive law” · 8 citing courts
15
GREENRosen v. St. Jude Med., Inc., 41 F. Supp. 3d 170 (N.D.N.Y. 2014).
cites § 814.84 1×cited by 26 cases
Where it cites § 814.84
“§ 360i; 21 C.F.R. §§ 814.84 (b)(2), 803.50(a); Riegel, 552 U.”
Later courts cite it for
“under new york law, 'to state a claim for manufacturing defect under theories of strict liability or negligence . . . the plaintiff must allege that (1) the product was defective due to an error in the manufacturing process and (2) the defect was the proximate cause of the plaintiff's injury.” · 4 citing courts
16
GREENWarstler v. Medtronic, Inc., 238 F. Supp. 3d 978 (N.D. Ohio 2017).
cites § 814.84 1×cited by 10 cases
Where it cites § 814.84
“These include reporting new clinical investigations or scientific studies that the manufacturer knows of or reasonably should know of, 21 C.F.R. § 814.84 (b)(2). In addition, the manufacturer must report incidents where the device either may have caused or contributed to death…”
17
GREENMcConologue v. Smith & Nephew, Inc., 8 F. Supp. 3d 93 (D. Conn. 2014).
cites § 814.84 1×cited by 22 cases
Where it cites § 814.84
“§ 360i; 21 C.F.R. §§ 814.84 (b)(2), 803.50(a); Riegel, 552 U.”
Later courts cite it for
“a manufacturing defect is a flaw in the manufacturing process which causes the product to deviate from the design standards and intended specifications.” · 3 citing courts
18
GREENScott v. CIBA Vision Corp., 38 Cal. App. 4th 307 (Ct. App. 1995).
cites § 814.84 1×cited by 53 cases
Where it cites § 814.84
“§ 360i; 21 C.F.R. § 814.84 (1995).) The MDA contains an express preemption provision at section 360k, which provides in subdivision (a) as follows: *316 “[N]o State or political subdivision of a State may establish or continue in effect with respect to a device intended for…”
The case’s holding
State tort claims for inadequate warnings are preempted by federal law when the device is a class III medical device subject to premarket approval.
Later courts cite it for
“we do not entertain issues raised for the first time in a reply brief, in the absence of a showing of good cause why such issues were not raised in the opening brief.” · 7 citing courts
19
GREENGlennen v. Allergan, Inc., 247 Cal. App. 4th 1 (Ct. App. 2016).
cites § 814.84 1×cited by 8 cases
Where it cites § 814.84
“versight regime following approval also generally subjects approved medical devices to continuing *9 recording and reporting requirements, including the obligation to inform the FDA of new clinical investigations or scientific studies concerning the device of which the…”
Later courts cite it for
“to survive preemption, a claim 'must be premised on conduct that both (1) violates the mda and (2) would give rise to a recovery under state law even in the absence of the mda.” · 1 citing court
20
GREENWilliams v. Smith & Nephew, Inc., 123 F. Supp. 3d 733 (D. Md. 2015).
cites § 814.84 1×cited by 18 cases
Where it cites § 814.84
“A device-maker has, for example, the obligation to inform the FDA of new clinical investigations or scientific studies concerning the device which the [device-maker] knows of or reasonably should know of, 21 C.F.R. § 814.84 (b)(2), and to report incidents in which the device may…”
The case’s holding
Failure-to-warn and manufacturing-defect claims against a premarket-approved medical device maker are not preempted, because they parallel federal requirements and rest on independent state tort duties.
Later courts cite it for
“the loss of consortium claim survives alongside those claims on which it depends.” · 2 citing courts

Show all 49 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199520102026

One bar per year. Tallest: 7 cases in 2013. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
M.D. Fla.5N.D. Ohio4Cal. Ct. App.32d Cir.2D. Conn.2N.D. Ill.2W.D. Ky.2D. Md.2

The 8 courts with the most citing cases, of 32 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 49 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com